Translating Regenerative Medicine to the Clinic

Introduction: Regenerative Medicine for Cardiovascular Disease-A Good Start
PART I: STEM CELLS:
Chapter 1: Introduction and Overview of Stem Cells
Chapter 2: Mechanistic Insights from Pathologic Perspective
Chapter 3: Large Animal Models to Study Stem Cell Therapy
Section I. Body's Native Repair Mechanisms
Chapter 4. Evolution of understanding of the mechanisms of repair
Chapter 5: Impact of Age on Stem Cell Function
Section II: Autologous Bone Marrow
Chapter 6: Bone Marrow Mononuclear Cells
Chapter 7: Chronic Limb Ischemia
Chapter 8: Chronic/Refractory Angina
Chapter 9: Acute Myocardial Infarction
A. European Experience: Andreas Zeiher
B. US Experience: Jay Traverse
Chapter 10: Chronic Ischemic Heart Failure
Section III: Autologous Adipose Derived Regenerative Cells
Chapter 11: Adipose Tissue
Section IV: Allogeneic Alternatives to Autologous Bone Marrow
Chapter 12: Overview of MSCs
Chapter 13: Allogeneic vs Autologous Source: Comparative Effects
Chapter 14: Use of MSCs for AMI
Chapter 15: Combined Cell Strategies
Chapter 16: Heart Failure
Section V: Cardiac Progenitor Cells
Chapter 17: C-Kit+ cells
Chapter 18: Cardiospheres
Section VI: Other Allogeneic Sources of Stem Cells
Chapter 19: Umbilical Cord, Placenta, Endometrium
Section VII. Genetic Engineering/Cell Transformation
Chapter 20: Genetic Engineering of Fibroblasts to Cardiomyocytes
Chapter 21: Transformation to inducible Pleuripotent Stem Cells
Chapter 22: Transformation to MAPC's
Section VIII: METHODS OF DELIVERY:
Chapter 23. Transcoronary and Endocardial
Chapter 24. Retrograde and Epicardial
Part II. TISSUE ENGINEERING:
Chapter 25. Epicardial Patch
Chapter 26. Matrix Scaffolds
Chapter 27. Matrix plus cells
Chapter 28. Biomaterial
Chapter 29: Organogenesis
Part III. GENE THERAPY:
Chapter 30: Pre-clinical Identification of target genes
Chapter 31: SERCA-2a gene for recovery of inotropic function
Chapter 32: SDF-1 Gene for Heart Failure Non-Inotropic

Dr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR. Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality.Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for